Therapy Areas: Oncology
1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
5 December 2019 - - The first patient enrolled in the dose escalation Phase 1 clinical study for French clinical-stage biopharmaceutical company Cellectis' (PAR: ALCLS) (NASDAQ: CLLS) (Euronext Growth: ALCLS) (NASDAQ: CLLS) UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center, the company said.

This clinical study, BALLI-01, will evaluate the safety, expansion, persistence and clinical activity of UCART22, a product candidate composed of engineered T-cells expressing anti-CD22 chimeric antigen receptors, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

UCART22 targets CD22, which is a B-cell restricted surface antigen expressed in normal B-lineage cells, as well as in blast cells from B-ALL and other B-cell malignancies.

The clinical trial is led by Dr. Nitin Jain, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (Houston, TX) in collaboration with Dr. Richard Larson, MD, director of the Hematologic Malignancies Clinical Research Program at the University of Chicago Medicine (Chicago, IL) and with Dr. Gail Roboz, MD, director, Clinical and Translational Leukemia Programs, Professor of Medicine, Weill Cornell Medical College The New York Presbyterian Hospital (New York, NY).

UCART22 is one of Cellectis' wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates, designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL.

B-cell acute lymphoblastic leukemia (B-ALL) is a hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood and other organs.

The increase and accumulation of blast cells in the bone marrow results in suppression of the normal production of blood cell and blood plasma components, and can therefore cause anemia, thrombocytopenia, neutropenia and risk of infection.

Acute lymphoblastic leukemia can start either with early B-cells or T-cells at different stages of maturity, however, approximately 85% of ALL cases involve precursor B-cells (B-ALL).

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients.

As a clinical-stage biopharmaceutical company with over 19 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilising TALEN, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system, to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia, B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma, Hodgkin lymphoma and non-Hodgkin lymphoma.

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the NASDAQ Global Market (NASDAQ: CLLS) and on Euronext Growth (ticker: ALCLS).